AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21224870
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (daily 2000 IU) for 10 weeks
Trial: 21224870
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (daily 2000 IU)
Trial: 21224870
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (daily 2000 IU) and Placebo
Trial: 19882059
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose paracetamol (40 mg/kg orally)
Trial: 11565628
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (n = 11) for 2 weeks
Trial: 3162901
Drug: Intravenous enoxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoxacin 200 mg
Trial: 3162901
Drug: Intravenous enoxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoxacin 800 mg
Trial: 3162901
Drug: Oral enoxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enoxacin 200 mg
Trial: 3162901
Drug: Oral enoxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enoxacin 800 mg
Trial: 20978247
Drug: Neostigmine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 50 μg/kg
Trial: 17180485
Drug: Milk drink
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk drink supplemented with whey peptides (125 ml every morning for 12 weeks)
Trial: 15539863
Drug: Rupatadine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 80 mg
Trial: 3169959
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of zinc sulphate orally thrice a day for one month
Trial: 21478756
Drug: Rabeprazole 0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 0.14 mg/kg (part 1)
Trial: 21478756
Drug: Rabeprazole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 0.5 mg/kg (part 2)
Trial: 21478756
Drug: Rabeprazole 1
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 1 mg/kg (part 2)
Trial: 21478756
Drug: Rabeprazole (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (0.14 mg/kg, 0.5 mg/kg, 1 mg/kg)
Trial: 15560155
Drug: Permixon (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permixon (320 mg/day for 3, 6, and 12 months)
Trial: 9070519
Drug: Desirudin (Revasc,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desirudin (Revasc, CGP 39393); 15 mg two times a day, administered subcutaneously for 8-11 days.
Trial: 9070519
Drug: Unfractionated heparin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin; 5000 international units three times a day, administered subcutaneously for 8-11 days.
Trial: 8379169
Drug: Cocktail-group received
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail-group received 100 ml of a homogenous fluorescein dilution
Trial: 8379169
Drug: Fraction-group received
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraction-group received 45 ml of unstained solution followed by 10 ml of concentrated dye
Trial: 3723496
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg TID
Trial: 23327695
Drug: Large dose
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dose of continuous veno-venous hemodiafiltration (CVVHDF) (70 ml×kg(‐1)×h(‐1), n = 9)
Trial: 23327695
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of CVVHDF (45 ml×kg(‐1)×h(‐1), n = 8)
Trial: 23327695
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of CVVHDF (25 ml×kg(‐1)×h(‐1), n = 11)
Trial: 20026597
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Trial: 20026597
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Trial: 12945073
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin (30 mg mupirocin calcium hydrate ointment topically to each nostril three times a day for 3 days before operation)
Trial: 9368506
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg orally every 6 h)
Trial: 8248954
Drug: colestipol/niacin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colestipol/niacin plus diet therapy
Trial: 8248954
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus diet therapy
Trial: 27754722
Drug: Resveratrol (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (1,500 mg p.o. daily)
Trial: 23014487
Drug: NaFeEDTA-fortified whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA-fortified whole wheat flour (6 mg of Fe)
Trial: 18948800
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation therapy with individual counseling and nicotine substitution starting 4 weeks before surgery and continuing 4 weeks postoperatively.
Trial: 18948800
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation therapy (abstainers).
Trial: 15781813
Drug: Laquinimod 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 0.3 mg
Trial: 15781813
Drug: Laquinimod 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 0.3 mg (subgroup with at least one active lesion at baseline)
Trial: 9778752
Drug: Combined cold-adapted
RxNorm normalized name: COLD REMEDIES,COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cold-adapted influenza A (H3N2) and trivalent inactivated influenza vaccine
Trial: 7880088
Drug: Meningococcal A
RxNorm normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal A and C polysaccharide vaccine
Trial: 2008283
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 0.06 meq/ml sodium bicarbonate (LPH)
Trial: 24977996
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (L)
Trial: 2008283
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine and 0.06 meq/ml sodium bicarbonate (LEPH)
Trial: 205828
Drug: p-aminosalicylic acid
RxNorm normalized name: p-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p-aminosalicylic acid (PAS) 150 mg/kg/day
Trial: 27651513
Drug: Simple Continuous
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Continuous Infusion
Trial: 27118470
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg)
Trial: 27118470
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Aspirin 300 mg, Aspirin 75 mg, Clopidogrel)
Trial: 9444449
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro in combination with NPH human insulin administered twice daily
Trial: 9444449
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin in combination with NPH human insulin administered twice daily
Trial: 7944443
Drug: Hepatectomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatectomy and coagulation therapy for remaining tumor
Trial: 7944443
Drug: Coagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulation therapy only
Trial: 3555566
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (verapamil 120 mg three times a day and atenolol 100 mg once a day)
Trial: 3555566
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg three times a day
Trial: 386061
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg once a day
Trial: 26255172
Drug: Stepping Stones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepping Stones Triple P (SSTP) plus Acceptance and Commitment Therapy (ACT)
Trial: 23954534
Drug: Steroids with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids with prompt delivery (PD group) after 48 hours
Trial: 23954534
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and expectant management (EXM group)
Trial: 23954534
Drug: Steroids with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids with prompt delivery (PD group)
Trial: 18799288
Drug: d-cycloserine 50
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-cycloserine 50 mg once-weekly
Trial: 28100438
Drug: 35 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/kg rifampicin per day with isoniazid, pyrazinamide, and ethambutol
Trial: 28100438
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Trial: 28100438
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Trial: 28100438
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and moxifloxacin
Trial: 28100438
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol)
Trial: 27208905
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (600 mg fixed dose)
Trial: 25403587
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (weight-based)
Trial: 25403587
Drug: Both subcutaneous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both subcutaneous and intravenous trastuzumab
Trial: 21813840
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diethylcarbamazine and albendazole (DEC/ALB)
Trial: 19076157
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg at 22.00 h every night
Trial: 15112170
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 400 mg, thrice daily the day before and day of the contrast procedure
Trial: 10782553
Drug: Coping-orientated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping-orientated group therapy
Trial: 29725798
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy group
Trial: 9133220
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine test
Trial: 9133220
Drug: Oral guanfacine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral guanfacine test
Trial: 26700096
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of fish oil (0.6 g/day of EPA and DHA) for 9 weeks
Trial: 20582542
Drug: Preincisional parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Preincisional parecoxib (40 mg IV 30 min before skin incision)
Trial: 20582542
Drug: Postincisional parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Postincisional parecoxib (40 mg IV 30 min after skin incision)
Trial: 20582542
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received patient-controlled analgesia (PCA) morphine
Trial: 15679759
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg b.d.
Trial: 12358621
Drug: Artemisinin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin (40 mg/kg over 3 days) plus placebo chloroquine
Trial: 12358621
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg over 3 days) plus placebo artemisinin
Trial: 10366800
Drug: SCF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF plus G-CSF
Trial: 17163251
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine
Trial: 23074206
Drug: PF‐04523655 3‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04523655 3‐mg intravitreal injections
Trial: 23074206
Drug: PF‐04523655 0.4‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04523655 0.4‐mg intravitreal injections
Trial: 23074206
Drug: PF‐04523655 1‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04523655 1‐mg intravitreal injections
Trial: 20925948
Drug: Tailored home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored home-based exercise twice weekly
Trial: 20925948
Drug: Group-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based exercise twice weekly in rehabilitation center
Trial: 18410585
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg melatonin and 100 mg SB‐73
Trial: 18410585
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Acyclovir
Trial: 1957409
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg, supplemented with half of the initial dosage if necessary)
Trial: 1957409
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg/kg, supplemented with half of the initial dosage if necessary)
Trial: 7343284
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU heparin-dihydroergotamine mesylate (Dihydergot)
Trial: 27819489
Drug: Progesterone (1
RxNorm normalized name: Fluorofuranylnorprogesterone (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (1 mg kg‐1 per 12 hours for 5 days)
Trial: 26449164
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for 48 weeks followed by treatment interruption (TI)
Trial: 23726041
Drug: Lebrikizumab 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 500 mg
Trial: 23726041
Drug: Lebrikizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab (all doses)
Trial: 17610805
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies targeting postprandial hyperglycemia
Trial: 15096971
Drug: N-13 ammonia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-13 ammonia (600 MBq or 16 mCi) administered intravenously
Trial: 11243303
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (CC) 4 mg to 8 mg once daily
Trial: 11243303
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 10 mg to 20 mg once daily
Trial: 9562226
Drug: Inhaled steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid plus theophylline
Trial: 9562226
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the steroid dose
Trial: 28576451
Drug: Elbasvir 50
RxNorm normalized name: elbasvir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group)
Trial: 28576451
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (deferred treatment group)
Trial: 25519790
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment group
Trial: 26070127
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen (estriol 50 μg/g gel, twice a week for 12 weeks)
Trial: 26070127
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid vaginal gel (once a day for 12 weeks)
Trial: 21548209
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vardenafil every other day for 12 weeks
Trial: 21548209
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E at 100 mg once a day for 12 weeks (Control)
Trial: 8067497
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/day for 1 week, then 40 mg/day for 5 weeks)
Trial: 27684533
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of trastuzumab and lapatinib
Trial: 19420195
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg three times daily for 28 days
Trial: 11728297
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide therapy
Trial: 15253732
Drug: Ramipril (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (6 mg/m2)
Trial: 11236072
Drug: Citalopram 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 60 mg/day
Trial: 11236072
Drug: Citalopram (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (all doses)
Trial: 11236072
Drug: Citalopram 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 60 mg and 20 mg
Trial: 9305229
Drug: Live active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live active yogurt containing L. acidophilus (225 g twice daily)
Trial: 9305229
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (yogurt without L. acidophilus)
Trial: 9305229
Drug: Live active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live active yogurt containing L. acidophilus
Trial: 3084344
Drug: Bowel rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bowel rest with parenteral nutrition
Trial: 9058440
Drug: Oral diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diet
Trial: 22795063
Drug: Moderate potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate potassium cold blood cardioplegia (K+, 10 mmol/L)
Trial: 22795063
Drug: High potassium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High potassium cold blood cardioplegia (K+, 20 mmol/L)
Trial: 19477776
Drug: Androgen ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen ablation treatment
Trial: 19477776
Drug: Literature on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literature on female breast cancer patients treated with hormones
Trial: 1852979
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks oral digoxin administration
Trial: 6334320
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base as enteric coated pellets (2 X 250 mg)
Trial: 6334320
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate tablet (1 X 500 mg)